胰十二指肠切除术后微透析监测患者的MINIMUM研究:随机对照试验方案
MINIMUM研究为前瞻性、随机、对照、单中心试验,计划纳入200例择期开放胰十二指肠切除术患者,1:1随机分为腹腔内微透析监测组与标准治疗组,主要目的是评估微透析能否缩短总住院时间,次要终点包括并发症频率、导管故障、感染出血事件、生活质量、疼痛及人均费用。
要点
- 腹腔内微透析可在胰肠吻合口局部监测代谢物,早于全身血检变化。
- 主要终点为总住院时间,次要终点涵盖并发症、导管安全性与费用。
- 研究注册号NCT03631173,方案版本19-1(2019年1月15日)。
核心结论
- 腹腔内微透析可能降低胰十二指肠切除术后并发症与死亡率,并有望缩短住院时间、减少费用。
- 研究假设为微透析较标准治疗可缩短总住院时间。
研究设计与样本
- 前瞻性、随机、对照、单中心试验,计划纳入200例择期开放胰十二指肠切除术患者。
- 患者按1:1随机分为微透析组(术中放置腹腔内微透析导管并监测)与标准治疗组(不放置导管,按现行标准监测)。
- 主要目的是评估微透析能否缩短总住院时间。
关键数值与推荐
- 主要终点:总住院时间。
- 次要终点:并发症频率、本院住院时间、导管故障、微透析导管所致感染与出血事件数、患者报告的生活质量与疼痛、每例胰十二指肠切除术患者费用。
- 试验注册:Clinicaltrials.gov NCT03631173,2018年9月7日注册,基于2019年1月15日方案版本19-1。
临床怎么用
- 术后除常规临床检查、影像学、胰周引流液淀粉酶及血检外,可考虑腹腔内微透析作为局部监测补充手段。
- 微透析导管置于胰肠吻合口处,用于监测腹腔内代谢物变化。
局限性
- 单中心设计,样本量200例,外部推广性需进一步验证。
- 研究为方案报告,尚未提供微透析有效性及安全性的结果数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative pancreatic fistula after pancreatoduodenectomy is a much-feared complication associated with substantial mortality and morbidity. The current standard for diagnosing postoperative pancreatic fistula, besides routine clinical examination, include radiological examinations, analysis of pancreatic drain amylase activity, and routine blood samples. Another promising method is by intraperitoneal microdialysis to monitor intraperitoneal metabolites measured at the pancreaticojejunostomy, thereby detecting what occurs locally, before chemical events can be reflected as measurable changes in systemic blood levels. METHODS: The MINIMUM study is a prospective, randomized, controlled, single center enrolling 200 patients scheduled for open pancreatoduodenectomy comparing the microdialysis method to the "standard of care." Half of the included patients will be randomized to receive an intraperitoneal microdialysis catheter implanted at the end of surgery and will be monitored by microdialysis as an additional monitoring tool. The other half of the patients will not receive a microdialysis catheter and will be monitored according to the current standard of care. The primary objective is to evaluate if the microdialysis method can reduce the total length of stay at the hospital. Secondary endpoints are the frequency of complications, length of stay at the hospital at our institution, catheter malfunction, number of infections and bleeding episodes caused by the microdialysis catheter, patient-reported quality of life and pain, and cost per patient undergoing pancreatoduodenectomy. The patients will be randomized in a 1:1 ratio. DISCUSSION: Intraabdominal microdialysis could potentially reduce morbidity and mortality after pancreatoduodenectomy. Furthermore, there is a great potential for shortening the in-hospital length of stay and reducing the financial aspect considerably. This study may potentially open the possibility for using microdialysis as standard monitoring in patients undergoing pancreatoduodenectomy. The hypothesis is that the microdialysis method compared to "standard care" will reduce the total length of hospital stay. TRIAL REGISTRATION: Clinicaltrials.gov ( NCT03631173 ). Registered on 7 September 2018 under the name: "Monitoring of patients With Microdialysis Following Pancreaticoduodenectomy". Based on protocol version 19-1, dated 15th January 2019.
引用
- Lindholm E, Ekiz N, Tønnessen TI, et al. Monitoring of patients with microdialysis following pancreaticoduodenectomy-the MINIMUM study: study protocol for a randomized controlled trial. Trials. 2021. PMID: 33962656. doi:10.1186/s13063-021-05221-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。